Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Queensland Health
Cantor Fitzgerald
McKesson
Chinese Patent Office

Generated: July 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DONEPEZIL HYDROCHLORIDE

Try a free trialSee Plans and Pricing

« Back to Dashboard

Clinical Trials for DONEPEZIL HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Summary
NCT00000173 Memory Impairment Study (Mild Cognitive Impairment Study) Completed Alzheimer's Disease Cooperative Study (ADCS) Phase 3 The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00000173 Memory Impairment Study (Mild Cognitive Impairment Study) Completed National Institute on Aging (NIA) Phase 3 The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00004807 Study of the Pathogenesis of Rett Syndrome Completed Johns Hopkins University N/A OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00004807 Study of the Pathogenesis of Rett Syndrome Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for DONEPEZIL HYDROCHLORIDE

Condition Name

Condition Name for DONEPEZIL HYDROCHLORIDE
Intervention Trials
Alzheimer's Disease 84
Alzheimer Disease 35
Healthy 21
Dementia 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for DONEPEZIL HYDROCHLORIDE
Intervention Trials
Alzheimer Disease 144
Dementia 48
Cognition Disorders 27
Mild Cognitive Impairment 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for DONEPEZIL HYDROCHLORIDE

Trials by Country

Trials by Country for DONEPEZIL HYDROCHLORIDE
Location Trials
United States 687
Japan 168
Canada 88
Germany 64
Korea, Republic of 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for DONEPEZIL HYDROCHLORIDE
Location Trials
California 49
Florida 44
New York 42
Texas 36
Arizona 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for DONEPEZIL HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for DONEPEZIL HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 68
Phase 3 46
Phase 2/Phase 3 2
[disabled in preview] 70
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for DONEPEZIL HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 163
Recruiting 39
Terminated 27
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for DONEPEZIL HYDROCHLORIDE

Sponsor Name

Sponsor Name for DONEPEZIL HYDROCHLORIDE
Sponsor Trials
Pfizer 31
Eisai Inc. 24
Eisai Co., Ltd. 11
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for DONEPEZIL HYDROCHLORIDE
Sponsor Trials
Industry 202
Other 182
NIH 34
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Moodys
QuintilesIMS
Mallinckrodt
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.